701. Artificial adjuvant vector cells 2.Cancer therapy with iPS-derived NKT cells 3. Drugs for allergic diseases 5. A novel inhibitor for HBV infection6. Abdrugs for IBD In collaboration with pharmaceutical companiesIdentification& validation of targetsTumor microenvironment (TME)Cancer cellsImmune cellsAnalysis of TMESeed/LeadidentificationLeadoptimizationEstablishment of therapeutic strategiesagainst cancerStratification of cancerOmics analysis of cancer cells and immune cellsCancer immunotherapy Figure: Collaboration between IMS and DMP for the development of innovative new pharmaceuticals and medical technologiesantigen-specific tumor rejection under certain conditions, however the tumors often evade the immune network. To ac-complish this escape, tumors may mediate immunosuppression through various soluble and cellular mechanisms. Understanding the role of the immune system in the tumor microenvironment (TME) will lead to a variety of specific approaches designed to initiate or enhance antitumor immunity (Figure). The groups in cancer immunology are using both murine models and human clinical samples from a variety of cancers to find crucial mol-ecules for therapy. Tsunoda’s group (Lab for Medical Science Mathematics) brought the ideas and methods from mathematics and computational sciences into play. They demonstrated the re-sults of immunogenomic analysis and provided a new classifica-tion of gastric cancer. This group also established a new method of quantifying multicellular colonization in tumor metastasis using NGS data. Nakagawa’s group (Lab for Cancer Genom-ics) analyzed genome and RNA sequence data from esophageal cancers and showed that the immune response in the TME was significantly corelated with the chemotherapy response. They also used RNA sequencing data to search for candidate drugs that could modulate the immune microenvironment. Ishikawa’s group (Lab for Human Disease Models) has identified acute myeloid leukemia (AML)-initiating cells by performing xenogeneic trans-plantation followed by DNA and RNA sequencing. By integrating maceuticals and medical technologies by facilitating the trans-fer of basic research within the institute. DMP was founded in RIKEN in 2010 in order to support all phases of development of new therapeutics, from the discovery of promising targets to the identification of potential lead compounds, such as small mol-ecules and antibodies, and the acquisition of intellectual property rights to drugs and technologies that can then be brought to the development phase.To achieve effective progress in this area, DMP established nine Drug Discovery Basic Units, in which the types of studies being performed are organized according to the expertise of each the results, they found critical molecules in individual patients and linked the vulnerabilities with AML initiating genetic events. Fujii’s group (Lab for Immunotherapy) identified immunogenic neoantigens and confirmed that DCs pulsed with these peptides elicited antitumor CTL responses. As part of the effort to develop translational research (TR) applications, Koseki’s group (Lab for Developmental Genetics) has started an iPS-NKT cell clinical trial for head and neck cancer. Fujii’s group has recently done an investigator-initiated Phase I clinical trial of aAVC-WT1 therapy against AML and is preparing for a phase II study. These TR projects have been supported by the RIKEN Drug Discovery and Medical Technology Platforms (DMP).PI. IMS contributes to this effort in several ways, including by set-ting up a facility for the development of antibody drugs, the Drug Discovery Antibody Platform Unit. In 2020, IMS now has six collaborative programs with DMP: Artificial adjuvant vector cells (Shin-ichiro Fujii), Cancer therapy with iPS-derived NKT cells (Haruhiko Koseki), Drugs for allergic diseases (Masato Kubo), neutralizing mAb for HBV infection (Daiki Miki) and therapeutic mAb for inflammatory bowel diseases (Takashi Saito). An investi-gator-initiated Phase I clinical trial of the Artificial adjuvant vec-tor cell project for cancer therapy has just been completed.PreclinicalpreclinicaldevelopmentdevelopmentClinical developmentCancer ImmunologyThe immune system recognizes tumor cells and can mediate Linkage to RIKEN Program for Drug Discovery and Medical Technology Platforms (DMP)IMS collaborates with DMP to develop innovative new phar-
元のページ ../index.html#76